BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 11, 2012
 |  BioCentury  |  Emerging Company Profile

Xdynia: T type relief

Xdynia targeting T type calcium channels in periphery for neuropathic pain

Xdynia LLC spun out from Tau Therapeutics Inc. this year to develop oral small molecule inhibitors of a specific subset of voltage-dependent T type calcium channels that play a prominent role in pain signal transduction. The approach could offer better safety and efficacy for neuropathic pain than available drugs.

According to President Yuri Maricich, up to 60% of patients report no relief from drugs commonly prescribed for neuropathic pain, such as GABA receptor agonists, selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) and opiates.

These drugs also have side effects ranging from somnolence and nausea to more serious risks including seizures and dependence.

Xdynia's compounds, which specifically block the calcium channel voltage-dependent T type alpha 1H subunit (CACNA1H; Cav3.2), should avoid most if not all of these side effects, Maricich said.


Read the full 664 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >